Weekly funding opportunities

[Med Research]

Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional)<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D264.html&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=yfjd2v2b-gC4rZRPOo5ianSftOjHtB9yl2TAsupVr_U&s=5DOU-22_H7n35uZ0KXblq-ihx7tZQQEbVd6MuakRTq4&e=>
This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other -omic integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests. N-dimensional co-registered, cross-correlated imaging results integrated with multiplexed biomarker data and digital pathomics using analytic strategies such as artificial intelligence and virtual reality visualization for improving discovery are encouraged. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives.
Due July 10, 2019; December 10, 2019; July 10, 2020; December 10, 2020; July 9, 2021; and December 10, 2021. Med-RA deadline to receive draft documents for July 2019 deadline: June 24.

American Diabetes Association: Core Research Program Awards<https://urldefense.proofpoint.com/v2/url?u=https-3A__professional.diabetes.org_meetings_core-2Dprogram-23custom-2Dcollapse-2D3-2Dminoritypostdoctoral-2Dfellowship-2Dpmf&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=yfjd2v2b-gC4rZRPOo5ianSftOjHtB9yl2TAsupVr_U&s=nDNdA6H06Tb5Hn0UnSrSMyaod54eU_4TpxOk3E8WvfQ&e=>
The American Diabetes Association’s Core Research Program funds research with novel and innovative hypotheses in any area relevant to the etiology or pathophysiology of diabetes and its complications that hold significant promise for advancing the prevention, cure or treatment of diabetes. Basic, clinical, translational and epidemiological or health services research approaches are encouraged.

Research Awards
Innovative Basic Science
Innovative Clinical or Translational Science

Development Awards
Junior Faculty Development
Minority Junior Faculty Development

Training Awards
Postdoctoral Fellowship
Minority Postdoctoral Fellowship

Applications for all awards due July 15, 2019. Med-RA deadline to receive draft documents: June 27.

American Association for Cancer Research: – Johnson & Johnson Lung Cancer Innovation Science Grants<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.aacr.org_Funding_Pages_Funding-2DDetail.aspx-3FItemID-3D71&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=yfjd2v2b-gC4rZRPOo5ianSftOjHtB9yl2TAsupVr_U&s=otqd18dK8WP0WOpic1_OgwLimaq3CJfP-lOhLaSFevU&e=>
The American Association for Cancer Research – Johnson & Johnson Lung Cancer Innovation Science Grants program is a joint effort to address the need for promoting and supporting collaborative cancer research in areas that include digital therapeutics and smoking cessation, as well as biomarkers/behavioral phenotyping that bolster understanding of how lung cancer can be successfully intercepted. To that end, a grant of $1 million over three years will be awarded to a multi-institutional team in support of a new idea and/or innovative approach that has direct application and relevance to lung cancer prevention and interception. The proposed research should be translational in nature and include a clinical component with an endpoint relevant to improving the detection or treatment of lung cancer. Priority areas of interest include clinical trials that identify unique high-risk patients for lung cancer and demonstrate sustained efficacy through the measurement of both quit rates as well as disease-related biomarkers; and clinical trials that identify digital therapeutics focused on smoking avoidance for first-time smokers or for former smokers (these therapeutics may consider the impact of social engagement, gaming, and other content relevant for a population at a risk of starting or resuming the smoking habit). The inclusion of a strategic plan for clinical confirmation of the digital therapeutic study is recommended.
Due July 19, 2019. Med-RA deadline to receive draft documents: July 8.

NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D258.html&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=yfjd2v2b-gC4rZRPOo5ianSftOjHtB9yl2TAsupVr_U&s=QbKie2s3eeft6Gb68afPGxjf4HGlp-lGUOH3QFxVe-0&e=>
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. This FOA is intended to support research education activities that enhance the knowledge of substance use (SU) and substance use disorder (SUD) research. The program is intended for those in clinically focused careers and/or those training for careers as clinicians/health service providers, clinical researchers, or optimally a combination of the two. This mechanism may not be used to support non-research-related clinical training.
To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on:

  *   Courses for Skills Development: Activities may include advanced courses in a specific discipline or research area, clinical procedures for research, neuroethics in clinical research, specialized research techniques, or other topics that would complement and enhance the research experiences proposed. Additionally, career development seminars and workshops such as grant writing, manuscript preparation, and building a successful career path are encouraged.
  *   Research Experiences: Activities include hands-on exposure to research for undergraduate students and research experiences for graduate and medical students, postdoctorates, and/or early career faculty.  The nature of research experiences should be tailored to the needs and career level of participants. It is expected that mentoring will be provided in conjunction with planned research experiences.
The proposed research education programs must include both courses for skills development and research experiences; however, primary emphasis should be given to research experiences.  Courses for skills development should be proposed in conjunction with research experiences.
Due July 22, 2019; July 22, 2020; and July 22, 2021. Med-RA deadline to receive draft documents for 2019 deadline: July 8.

HLA and KIR Region Genomics in Immune-Mediated Diseases (U01 / U19 Clinical Trial Not Allowed)
U01<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DAI-2D19-2D041.html&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=yfjd2v2b-gC4rZRPOo5ianSftOjHtB9yl2TAsupVr_U&s=H6Hgk84oB1Aofkts97cwwAz9PO3I8SwtFVzi1TQ7sk0&e=>
U19<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DAI-2D19-2D044.html&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=yfjd2v2b-gC4rZRPOo5ianSftOjHtB9yl2TAsupVr_U&s=WGkQkUlxtUrSu-9MaUTf7TXWfo4qWM4FfAYobMzskh0&e=>
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLARGC). This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and organ transplantation.
Due September 4, 2019. Med-RA deadline to receive draft documents: August 21.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20190506/a8aa0d27/attachment.html>